Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer

Journal of Cancer Research and Practice

卷:1

Tzung-De Wang¹  Chi-Feng Hung¹  Ming-Yuan Li²  Skye Hung-Chun Cheng³  Ben-Long Yu⁴  Chi-Feng Chung⁵  Wei-Hsin Liu⁵  Mei-Ching Liu⁵ 

[1] Department of Gynecology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan;

[2] Department of Pathology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan;

[3] Department of Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan;

[4] Division of General Surgery, Department of Surgery, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan;

[5] Division of Hematology and Oncology, Department of Internal Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan;

关键词: trastuzumab;    locally advanced breast cancer;    neoadjuvant therapy;    pathologic complete response (pCR);   

DOI  :  10.6323/JCRP.2014.1.2.11

来源: DOAJ

【 摘 要 】

Trastuzumab, a humanized monoclonal antibody directed against the external domain of the HER-2 protein, has shown remarkable activity against HER-2 positive breast cancer. Consequently, the use of adjuvant trastuzumab plus chemotherapy in patients with HER2-positive stage breast cancer (stage I to III) has become the standard treatment option. However, the role of trastuzumab in neoadjuvant treatment therapy is still uncertain. An increasing number of clinical trials and inadequate analysis show the benefit of adding trastuzumab to chemotherapy in the neoadjuvant setting. We report a case of HER2-positive locally advanced breast cancer in a patient who received cytotoxic agents concomitant with trastuzumab as neoadjuvant therapy, and also review the published literature. The patient achieved pathological complete response, and remained disease-free for more than 5 years.

【 授权许可】

Unknown